May 17th 2024
The FDA has given the novel agent NVL-655 a breakthrough therapy designation for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Unanswered Questions About Adjuvant Osimertinib in Resectable NSCLC
February 1st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Balazs Halmos, MD, discussed with participants how they interpret the ADAURA trial and the approach to adjuvant targeted therapy in non–small cell lung cancer This is the second of two articles based on this event.
Read More
Molecular Genotyping and its Association with OS in Metastatic NSCLC
January 24th 2024In an interview with Targeted Oncology, Charu Aggarwal, MD, MPH, discussed the real-world study evaluating the link between molecular genotyping and survival among patients with non–small-cell lung cancer.
Read More
Determining Optimal IO Combinations in Advanced NSCLC
January 6th 2024Sarah B. Goldberg, MD, MPH, presented these findings to demonstrate the effective time to use immuno-oncology combination therapy during the 41st Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow.
Read More
Role of Biomarkers in Deciding Neoadjuvant/Adjuvant Approach in NSCLC
January 3rd 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Balazs Halmos, MD, discussed with participants how they would approach the case of a patient with T3N0 lung adenocarcinoma of stage IIB. This is the first of 2 articles based on this event.
Read More
Repotrectinib Shows Improvement Over First-Generation TKIs in ROS1+ NSCLC
January 2nd 2024Firas B. Badin, MD, discusses the improvements seen with repotrectinib compared with first-generation ROS1-targeting tyrosine kinase inhibitors for patients with advanced ROS1-positive non–small cell lung cancer.
Watch
Phase 1 Study of Galinpepimut-S and Nivolumab Meets Primary End Point in MPM
January 2nd 2024In a phase 1 study of 10 evaluable patients with refractory/relapsed malignant pleural mesothelioma, the median overall survival was 17.6 months for patients treated with the combination of galinpepimut-S and nivolumab.
Read More
NSCLC: Initial Impressions of Patient Profile and Biomarker Testing Practices
December 19th 2023A medical oncologist offers his initial impressions of the patient profile of a 60-year-old with early-stage NSCLC and discusses biomarker testing practices, highlighting types of testing and challenges.
Watch